Editorial Board

Source: Transplantation Reviews - Category: Transplant Surgery Source Type: research

Related Links:

Journal Name: Clinical Chemistry and Laboratory Medicine (CCLM) Issue: Ahead of print
Source: Clinical Chemistry and Laboratory Medicine - Category: Laboratory Medicine Source Type: research
I spent my early and mid-career years working in a pediatric intensive care unit (PICU) at a large academic center. We did almost everything except for a few things esoteric at the time — small bowel transplants, a few kinds of experimental surgery. I’m now in my late career (but have no plans to quit […]Find jobs at  Careers by KevinMD.com.  Search thousands of physician, PA, NP, and CRNA jobs now.  Learn more.
Source: Kevin, M.D. - Medical Weblog - Category: General Medicine Authors: Tags: Policy Hospital-Based Medicine Pediatrics Source Type: blogs
AbstractThe foundation of the treatment of heart failure with reduced ejection fraction is a number of pharmacotherapies shown to reduce morbidity and mortality in large randomised multinational clinical trials. These include angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists, and more recently, a combined angiotensin receptor blocker neprilysin inhibitor, sacubitril/valsartan. In select cases, digoxin, ivabradine and hydralazine with isosorbide dinitrate have a role to play in the treatment of heart failure with reduced ejection fraction. On this ...
Source: Drugs and Aging - Category: Geriatrics Source Type: research
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
ConclusionEfforts to improve QOL30 of HSCT patients and caregivers in the confined environment of an HHH should focus on patients with low baseline QOL and older patients.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Jean El-Cheikh, Rana Salem, Radwan Massoud, Charelle Salem, Nohra Ghaoui, Souha S. Kanj, Rami Mahfouz, Ali Bazarbachi
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 December 2018Source: Hematology/Oncology and Stem Cell TherapyAuthor(s): Ghulam Rehman Mohyuddin, John Roller, Leyla Shune, Tara Lin, Ajoy Dias, Siddhartha Ganguly, Sunil Abhyankar, Joseph McGuirk, Anurag Singh
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Condition:   Dexmedetomidine, Liver Transplantation, Allograft Function, Survival Interventions:   Drug: Dexmedetomidine;   Drug: Saline Sponsor:   RenJi Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 10 December 2018Source: Antiviral ResearchAuthor(s): Long Tan, Noriaki Sato, Atsuko Shiraki, Motoko Yanagita, Yoshihiro Yoshida, Yoshinori Takemura, Kimiyasu ShirakiAbstractEverolimus is an inhibitor of mammalian target of rapamycin (mTOR) and reduces the risk of cytomegalovirus (CMV) infection in transplant recipients. Everolimus inhibits mTOR complex 1, which regulates factors involved in several crucial cellular functions and is required for CMV replication. However, it is not clear how everolimus regulates CMV replication and prevents and alleviates CMV infection. Effects of everolimu...
Source: Antiviral Therapy - Category: Virology Source Type: research
MONDAY, Dec. 10, 2018 -- Transplant patients with hearts from donors with hepatitis C virus (HCV) infection and obese donors have similar survival rates as patients with other donor hearts, according to two studies published in the December issue...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Transplant Surgery | Transplants